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Over the past few years, there have been substantial advances in our understanding of sarcoidosis
immunopathogenesis. Conversely, the etiology of the disease remains obscure for a number of reasons,
including heterogeneity of clinical manifestations, often overlapping with other disorders, and insensitive
and nonspecific diagnostic tests. While no cause has been definitely confirmed, there is increasing evidence
that one or more infectious agents may cause the disease, although the organism may no longer be viable.
Here we present 2 cases, in which sarcoidosis preceded tuberculosis and non-Hodgkin lymphoma.
Development of new lesions in a patient with chronic/remitting sarcoidosis should be looked at with
suspicion and promptly investigated in order to rule out an alternative/concomitant diagnosis. In such
cases, tissue confirmation from the most accessible site, and bone marrow biopsy—if lymphoma is in the
differential diagnosis—should be performed. In conclusion, we strongly advise that physicians be ready to
reconsider the diagnosis of sarcoidosis in the presence of atypical manifestations or persistent/progressive
disease despite conventional therapy.
© 2012 Elsevier Inc. All rights reserved. • The American Journal of Medicine (2012) 125, 118-125
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tWhen a thing ceases to be a subject of controversy, it ceases
to be a subject of interest.
William Hazlitt
Sarcoidosis is a systemic inflammatory disorder of un-
known etiology, characterized pathologically by noncaseat-
ing epithelioid cell granulomas—primarily affecting the
lungs and the lymphatics—and clinically by variable man-
ifestations and course. While remission, with or without
treatment, occurs in the majority of cases, sarcoidosis may
persist as chronic disease in up to one third of patients,
causing significant morbidity.1 Currently, the consensus
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ed.2011.06.003iew is that sarcoidosis is triggered by persistent presenta-
ion of as-yet unidentified, poorly degradable antigen(s) in
enetically susceptible hosts, thus triggering a Th1-type
ellular immune response leading to granuloma formation.
he diagnosis is established when compatible clinicoradio-
ogical features are supported by histological evidence of
oncaseating epithelioid granulomas.2 In the absence of a
nown etiology, sarcoidosis remains a diagnosis of exclu-
ion owing to the lack of definitive diagnostic blood, skin,
r radiologic imaging tests specific for the disorder.
The recommended approach to all patients at presenta-
ion involves a series of routine screening tests in order to
ssess the severity of organ involvement (Table 1). Histo-
ogical confirmation of the diagnosis should be obtained
herever possible. However, a CD4/CD8 T lymphocyte
atio higher than 3.5 in bronchoalveolar lavage fluid (BAL),
ngiotensin-converting enzyme (ACE) levels twice higher
han the upper normal limit, typical abnormal calcium me-
abolism, and negative bacterial or fungal cultures may be
elpful in establishing the diagnosis.2
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119Spagnolo et al Sarcoidosis and Mycobacterium TuberculosisCLINICAL CASE 1
A 58-year-old man, a lifelong nonsmoker, had been previ-
ously diagnosed with sarcoidosis (based on transbronchial
biopsies showing epithelioid non-necrotizing granulomas
and compatible clinicoradiologic features) and successfully
treated with oral steroids for 6
months (Figure 1). At that time,
tuberculin skin test was negative.
Nine years later he presented with
3 months history of night fever
(up to 39°C), abdominal pain (left
upper quadrant), fatigue, and
weight loss. The patient was re-
ferred to our chest clinic because
of lack of response to broad-spec-
trum antibiotics. An abdominal ul-
trasound showed enlarged spleen
and liver with concomitant ascites.
A recurrence of sarcoidosis was
suspected, and the patient was
started on 40 mg daily of oral
prednisolone, with rapid improve-
ment. However, as the steroids
were tapered, intermittent night
fever and abdominal pain re-
curred. Subsequently, the patient
developed left pleural effusion
and severe pancytopenia. Both pleural fluid and bone mar-
row cultures were negative for acid-fast bacilli and fungal
stain. As the patient continued to deteriorate, he underwent
splenectomy and drainage of ascitic fluid, which revealed the
presence of Mycobacterium tuberculosis (Figure 2). The pa-
tient was treated with standard antituberculosis therapy for 6
months and fully recovered. After 3 years’ follow-up he is
completely asymptomatic.
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Table 1 Recommended Initial Evaluation of New Sarcoidosis
Patients
Thorough past medical history (including family history), with
emphasis on occupational and environmental exposure
Physical examination, looking for pulmonary, cutaneous, ocular,
cardiac, hepatic, neurological, or splenic involvement
Chest radiography
Pulmonary function tests: spirometry with measurement of
diffusing capacity of carbon monoxide
Full blood counts
Serum chemistries: calcium, hepatic, and renal function, CRP,
ESR, ACE
24-hour urinary calcium excretion
ECG
Routine ophthalmologic examination
Tuberculin skin test
Other tests depending on clinical manifestations and suspicion
of specific organ involvement
ACE angiotensin-converting enzyme; CRP C-reactive protein;
ECG electrocardiogram; ESR erythrocyte sedimentation rate.This case raises, among others, 2 intriguing questions:
was the disease tuberculosis masquerading as sarcoidosis
from the very beginning? This is unlikely because the pa-
tient fully recovered following steroid therapy. Was tuber-
culosis a late complication of sarcoidosis in a patient treated
with corticosteroids? Differentiat-
ing sarcoidosis from tuberculosis
can be tricky. In fact, in addition to
producing granulomas, which occa-
sionally can be necrotizing in sar-
coidosis and non-necrotizing in tuber-
culosis,3,4 both diseases can affect the
same organs, thus sharing common
symptoms, both respiratory, such as
cough and dyspnea, and systemic,
such as fever, malaise, fatigue, and
weight loss.5
Evidence for a Microbial
Cause
Abundant evidence suggests that
sarcoid granulomas develop in re-
sponse to persistent, poorly de-
gradable antigenic stimuli. First,
immune granulomas form in re-
sponse to antigenic epitopes after
infection with organisms such as Schistosoma or mycobac-
eria.6,7 Inorganic agents as well as organic particulates also
may initiate pulmonary immune granulomas, the factor com-
mon to all being their low biodegradability and persistence,
often within macrophages.8 These intriguing etiologic theories
for sarcoidosis have, however, not endured.9
More traditional etiologic hypotheses point to infective/
transmissible agents, the concept being supported by the
finding of granulomas in the lungs of transplants from
donors known or suspected to have sarcoidosis.10 In addi-
tion, a granulomatous response can be produced by passag-
ing pooled, filtered homogenates of mouse granulomatous
tissue into other mice.11 Of note, organisms having the
characteristics of M. tuberculosis were grown from some of
these homogenates. However, the most persuasive evidence
that sarcoidosis is a transmissible disease remains the
Kveim-Siltzbach test—the intradermal inoculation of a pro-
tein extract of sarcoidosis lymph node or spleen that elicits
an oligoclonal T-cell response and non-caseating granuloma
formation in patients with sarcoidosis.12-14 The Kveim test
s no longer used.
Since its first description, sarcoidosis has been thought to
e related somehow to tuberculosis, and recent molecular
nd immunologic studies have revitalized interest in the
ausal role of mycobacteria in sarcoidosis. Using mycobac-
eria-specific primers and polymerase chain reaction (PCR),
ycobacterial DNA has been identified in 7 of 16 sarcoid-
sis specimens, compared with 1 of 16 normal controls and
of 4 disease controls with tuberculosis.15 More recent
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120 The American Journal of Medicine, Vol 125, No 2, February 2012specific to Mycobacterium species in sarcoidosis tissues at a
much higher rate than in tuberculosis-negative controls.16
Similarly, 60% of lung and lymph node tissue have been
reported to contain mycobacterial DNA, most of which
were classified as M. tuberculosis.17
New evidence may explain why highly sensitive molec-
ular techniques, such as PCR, may fail to identify the
genetic fingerprint of infectious agents in tissues of sarcoid-
osis patients. Using selective proteomic analysis of poorly
soluble protein aggregates derived from affected tissues,
Song and co-workers18 identified mycobacterial catalase-
eroxidase (mKatG) DNA in most sarcoidosis biopsy spec-
mens, but in none of the disease-free controls. In addition,
rake and co-workers,19 using enzyme-linked immunospot
ELISPOT) assays, detected a specific Th-1 immune re-
ponse to M. tuberculosis early secretory antigenic target 6
ESAT-6) and KatG peptides from peripheral blood mono-
uclear cells from sarcoidosis patients (15 of 26) and puri-
ed-protein-derivative (PPD) subjects (7 of 8) but not
rom PPD subjects (1 of 24), thus providing an immuno-
Figure 1 Computed tomography (CT) scan revealing upper
lobe predominant peribronchovascular fibrotic masses. There is
minimal bronchial distortion or bronchovascular deformation
(A). Nine years later, the fibrotic masses appear unchanged. CTb
scan reveals left pleural effusion (arrow; B).ogic link between mycobacteria and sarcoidosis.19 Further-
more, an increased BAL T-cell reactivity to mKatG has re-
cently been shown in sarcoidosis patients, fuelling the
speculation that, in at least some cases, the disease may result
from an immune response initiated by mycobacteria.20
Sarcoidosis has been suspected to be an infectious dis-
ease, but no microbial pathogen has consistently been iso-
lated or cultured so far. Alternatively, sarcoidosis may not
be related to a specific exposure but rather to an abnormal
immunologic host response to several agents, which would
explain why many studies have come to conflicting conclu-
sions about the cause/s of the disease. This concept, together
with the wide range of its clinical manifestations, suggests
that sarcoidosis may represent a family of diseases (sarcoid-
oses), each driven by a specific etiologic agent.21 Future
tudies investigating genetic risk factors could explain why
ome patients are found to have an association with micro-
Figure 2 Tuberculous perisplenitis. Well-formed non-necro-
tizing granulomas (A, arrows); Mycobacterium tuberculosis
(stained red) in perisplenic tissue (blue; B). A. Hematoxylin-
eosin, 100 (courtesy Dr Alberto Cavazza). B. Ziehl-Neelsen,
1000 (courtesy Dr Alberto Cavazza).ial antigens and others are not.
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A 76-year-old woman, a lifelong nonsmoker, presented to
our chest clinic with persistent high fever (up to 40°C). She
had been diagnosed 12 months earlier with a cutaneous
diffuse follicular lymphoma, which did not require any
systemic treatment. Chest radiograph and computed tomog-
raphy (CT) scan showed multiple enlarged mediastinal and
hilar lymph nodes (Figure 3A). She underwent bronchos-
copy with BAL, which revealed mild lymphocytosis (18%)
with a normal CD4/CD8 ratio, and multiple transbronchial
biopsies, showing epitheliod noncaseating granulomas, thus
suggestive of sarcoidosis (Figure 4). She was started on oral
steroids, with rapid improvement both clinically and radio-
logically (Figure 3B). Eight months later, the patient again
became symptomatic, complaining of persistent fever, mal-
Figure 3 Chest radiograph showing bilateral hilar lymph
adenopathy (A), which rapidly and completely regressed after
steroid therapy (B).aise, and weight loss. A chest radiograph and CT scan were
performed and were essentially unremarkable and un-
changed compared with previous ones, while an abdominal
CT scan revealed an enlarged spleen. Serum ACE was
elevated at 165 g/L (normal range 0-40). In addition, the
atient developed severe pancytopenia and underwent bone
arrow biopsy. Sadly, she deteriorated rapidly and died due
o multiple organ failure. A few hours later we received the
istology report of her bone marrow biopsy. The patient had
n anaplastic large cell B lymphoma (Figure 5A, B, and C).
Several studies of coexistent sarcoidosis and malignancy
uggest that this association is not fortuitous.22-24 Sarcoid-
sis may precede, follow, or occur concurrently with a
umber of cancers, including hematological malignancies—
ostly lymphomas—and solid tumors.23 Sarcoid-like reac-
tions occurring either adjacent to the primary malignant site
or to local drainage nodes, also are common, but these
Figure 4 Transbronchial biopsy showing well-formed non-
necrotizing granulomas with lymphangitic distribution (A);
higher magnification of the same biopsy (B). A. Hematoxylin-
eosin, 40 (courtesy Dr Giulio Rossi). B. Hematoxylin-eosin,
200 (courtesy Dr Giulio Rossi).should not be regarded as sarcoidosis.
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Malignancies
The incidence of lymphoproliferative disorders is higher
among sarcoidosis patients as compared with the general
population. While the precise mechanism of this association
is unclear, the chronic active type of sarcoidosis appears to
be responsible for an increased risk of malignant transfor-
mation of lymphoid cells.25 The term sarcoidosis-lym-
phoma syndrome coined by Brincker26 refers to chronic
active sarcoidosis preceding the diagnosis of lymphoma,
usually by several years. These patients are usually older
than 40 years, and the associated lymphoma is most fre-
quently a Hodgkin disease followed, in terms of frequency,
by non-Hodgkin lymphomas.22,23,27 Persistent active sar-
oidosis, anergy, and lymphopenia are usually associated
ith the syndrome.28 On the other hand, patients with he-
matologic malignancies (Hodgkin and non-Hodgkin lym-
phoma but also T-cell lymphoma, mycosis fungoides,
chronic lymphocytic leukemia, nonlymphocytic leukemia)
may subsequently develop sarcoidosis. One possibility is
that sarcoidosis in these patients is triggered by the immu-
nosuppressive treatment used for the underlying hemato-
logic malignancy. In fact, sarcoidosis following chemother-
apy has been reported in hematologic malignancies, with
alpha interferon being the agent most commonly associated
with development of sarcoidosis.29
Sarcoidosis and Solid Tumors
Convincing evidence suggests an increased frequency of
solid tumors in patients with sarcoidosis.23,30 Specifically,
organs previously affected by sarcoidosis appear to be at
increased risk of developing solid tumors, likely as a con-
sequence of the sarcoidosis-associated chronic inflamma-
tion.31 Conversely, sarcoidosis has been reported to occur
ollowing solid tumors of the cervix, liver, lung, skin (both
elanoma and nonmelanoma skin cancers), testicles, and
terus, among others.30,32,33 A strong association between
arcoidosis and testicular cancer (mostly seminoma) exists:
n these cases, sarcoidosis commonly follows the diagnosis
f cancer, although up to one third of patients are concom-
tantly diagnosed with sarcoidosis and testicular cancer.
hen occurring concomitantly, the 2 disorders seem to
ollow a relatively benign course.34
Sarcoid-like Reactions and Malignancies
Sarcoid-like reactions are defined as the presence of nonca-
seating granulomas in patients who do not fulfill the diag-
nostic criteria for systemic sarcoidosis.23 In patients af-
ected by malignancies, sarcoid-like reactions are usually
bserved in the lymph nodes draining the cancer. Neverthe-
ess, they also may occur in the organ of tumor origin or at
istant sites; this latter situation representing diagnostically
he most challenging one. Cancer-associated sarcoid-like
eactions have been observed both in patients with hema-
ologic malignancies (chronic lymphocytic leukemia,Figure 5 Bone marrow biopsy showing numerous macro-
phages in hemophagocytic activity (A); 2 large anaplastic cells
(arrows, B); immunohistochemistry showing CD20 malig-
nant cells (C). A. Hematoxylin-Eosin, 400 (courtesy Dr
Goretta Bonacorsi). B. Hematoxylin-Eosin, 400 (courtesy Dr
Goretta Bonacorsi). C. Immunohistochemistry of the same bi-hronic myelogenous leukemia, Hodgkin or non-Hodgkin
123Spagnolo et al Sarcoidosis and Mycobacterium Tuberculosisdisease, T-cell lymphoma, among others) and solid tumors.
Whether the presence of sarcoid-like reactions correlates
with better prognosis of the associated neoplasms is unclear.
Differentiating sarcoid-like reactions from systemic sar-
coidosis is vital, as a wrong diagnosis of sarcoidosis and the
subsequent delay in properly treating the underlying malig-
nancy can be catastrophic. Both cancer and sarcoidosis are
18F-fluorodeoxyglucose avid; therefore, the positron emis-
sion tomography scan may be useful in selecting possible
biopsy sites—by identifying organ involvement not appre-
ciated by routine methodology—but not in differentiating
between the 2 entities. If uncertainty remains, multiple bi-
opsies may be needed in order to determine whether all
fluorodeoxyglucose-avid nodes are involved with sarcoid-
osis or harbor cancer as well.
CONCLUDING REMARKS
The diagnosis of sarcoidosis requires the presence of a
compatible clinical/radiographic picture, histologic evi-
dence of noncaseating granulomas, and exclusion of known
causes of granulomatous inflammation. Sarcoid granulomas
can occur with varying rates in any organ system, but are
most commonly found in the lungs and lymph nodes. Pa-
tients may be entirely asymptomatic and the condition dis-
covered by the presence of characteristic findings on routine
health screening chest radiographs (30%-60% of cases) or
present with a wide range of manifestations, including re-
spiratory (dry cough, chest pain), ocular (pain, visual
change), and constitutional (fever, fatigue) symptoms, or
skin rashes (erythema nodosum, nodules, plaques, papules).
The most common radiological features include enlarged
bilateral hilar and right paratracheal lymph nodes. Fre-
quently, sarcoidosis affects individuals aged 20 to 40 years;
when it presents in persons older than 40 years, it is often
associated with the development of chronic progressive
disease. The acute onset of erythema nodosum or periartic-
ular ankle inflammation, bilateral hilar lymphadenopathy
(with or without fever and uveitis)—known as Löfgren
syndrome—is typically associated with a benign, self-lim-
iting disease course.35
While a positive biopsy is self-proving of diseases such
as lymphoma or tuberculosis, an (isolated) biopsy is never
diagnostic of sarcoidosis. Therefore, particularly in the pres-
ence of atypical manifestations (ie, unilateral hilar lymph-
adenopathy or isolated mediastinal lymphadenopathy with-
out hilar lymph node enlargement) or unexpected clinical
courses, histological evidence of noncaseating epithelioid-
cell granulomas from a single site should be considered
insufficient to make the diagnosis beyond doubt because no
morphological feature is pathognomonic of sarcoidosis (Ta-
ble 2). One clue that sarcoidosis may not be the correct
diagnosis is the patient’s failure to respond to corticosteroid
therapy. Another important hint concerns, among others, the
appearance of the spleen on the abdominal CT scan, in the
case of spleen involvement. Splenic sarcoidosis usually
appears as low-attenuation nodules that may coalesce intomass-like lesions.36 In our patients (both case 1 and case 2),
the spleen appeared quite enlarged but without evidence of
low-attenuation lesions. Furthermore, sarcoidosis is rare in
the elderly (case 2).
New organ involvement from sarcoidosis is rare after2
years from initial diagnosis. In addition, once the disease
remits, it rarely recurs; this implies that such unusual cir-
cumstances should be suspected of having an alternative
explanation. For instance, the development of a new solitary
nodule (particularly in a current or ex-smoker), asymmetri-
cal hilar, or peripheral lymphadenopathy in a patient on a
previously effective treatment regimen or after a prolonged
period of remission is more likely to be due to infection or
neoplasm and should not be attributed to recurrence of
sarcoidosis—even if the original diagnosis was histologi-
cally confirmed.37 Conversely, the presence of numerous
pulmonary nodules would be more in keeping with sarcoid-
osis than lung cancer, although both diagnoses remain pos-
sible. In challenging instances or if malignancy is suspected,
the diagnosis should be substantiated by mediastinal lymph
node or open lung biopsy. In selected cases, a trial of
corticosteroids may be justified to assess whether there is a
clinical response consistent with sarcoidosis, bearing in
mind that corticosteroids may induce a temporary/incom-
plete remission of lymphomas mistakenly diagnosed as sys-
temic sarcoidosis, thus delaying the correct diagnosis and
treatment.
Sarcoidosis granulomatous inflammation may develop in
unusual locations, thus causing atypical patterns of organ
involvement and posing a diagnostic challenge. Neverthe-
less, unexpected disease behaviors, such as the ones we
have described, also should raise the suspicion of alterna-
Table 2 Causes of Granulomatous Lung Disease
Infectious Agents
Mycobacteria (Myobacterium tuberculosis, atypical mycobacterial
infection)
Fungi (histoplasmosis)
Bacteria (brucellosis, chlamydial infection)
Spirochetes (treponemal infections)
Parasites (leishmaniasis, toxoplasmosis)
Occupational/environmental exposures
Organic agents (hypersensitivity pneumonitis)
Inorganic agents (beryllium, aluminium, talc, titanium,
zirconium)
Other conditions
Foreign body
Lymphomatoid granulomatosis
Cancer (lymphoma, sarcoid-like reactions)
Autoimmune disorders (Wegener granulomatosis, primary biliary
cirrhosis, Churg-Strauss syndrome)
Langerhans cell histiocytosis
Bronchocentric granulomatosis
Sarcoidosis
Adapted from: Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl
J Med. 1997;336:1224-1234.5tive/concomitant processes. Constitutional symptoms, he-
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liver, spleen, lymph nodes, and bone marrow, among oth-
ers—represent nonspecific findings and do not help in dif-
ferentiating sarcoidosis from neoplasm or infection. Histo-
logical confirmation of the diagnosis is therefore warranted
if uncertainty persists. However, even in the presence of
noncaseating granulomas, physicians should not be tempted
to stop looking for known causes of granulomatous disease
unless clinicoradiographic features compatible with sarcoid-
osis also are present. For instance, because chronic beryl-
lium disease is pathologically and clinically indistinguish-
able from sarcoidosis, a beryllium lymphocyte-proliferation
test looking at beryllium-specific T-lymphocyte activation
should be offered to any patient evaluated for suspected
sarcoidosis who has worked around metal dust or fumes.
The diagnosis of sarcoidosis may not be straightforward,
and patients often report a prolonged work-up period before
receiving the correct diagnosis.38 This is particularly true
or isolated ocular or cutaneous disease. Conversely, com-
inations of typical clinical and radiographic features—
symptomatic symmetrical bilateral hilar lymphadenopathy
ccompanied by erythema nodosum and ankle swelling—
re generally sufficient to establish a diagnosis of sarcoid-
sis rapidly and with little margin of error. If a clinical
anifestation deviates from that expected, or defining an
Figure 6 Diagnostic flow chart in patients with suspected s
Sarcoidosis. Lancet. 2003;361:1111-1118.39lternative diagnosis cannot be delayed, biopsy of the in-olved organ—possibly by sampling multiple sites—should
e considered, even when there is documentation of a prior
iopsy confirming an original diagnosis of sarcoidosis. Fig-
re 6 outlines a simplified diagnostic algorithm for patients
ith suspected sarcoidosis.
The implications of the cases we have discussed are
-fold:
● Sarcoidosis may precede, follow, or occur concurrently
with malignancies and tuberculosis, thus representing a
diagnostic challenge;
● Physicians should be ready to reconsider their initial
diagnosis of sarcoidosis in the presence of atypical man-
ifestations or persistent/progressive disease despite con-
ventional therapy;
● Clinical acumen remains key for correct interpretation of
clinical, radiological, and histological data, particularly if
unusual manifestations or unexpected disease behaviors
arise.
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